Revvity Inc., US76155R1086

Revvity stock holds near a 52-week high after Q2 beat

Published on 08/26/2026 at 10:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revvity stock trades near its 52-week high after a Q2 beat, with August 4 results showing $1.41 EPS and $729.69 million revenue.

Aquarell eines Forschungscampus mit Glasfassaden bei Sonnenuntergang
Aquarellmalerei zeigt Forschungscampus im Stil von Revvity Inc. (ISIN US76155R1086) bei goldenem Abendlicht am Wasser, Illustration mit AI erstellt.

Revvity Inc. (US76155R1086) stock opened at $123.08 on August 25, 2026, after a Q2 result that showed $1.41 EPS on $729.69 million revenue and a 12-month high of $124.97.

The latest figures, reported for the quarter ended August 4, 2026, also showed revenue down 1.3% from the same quarter a year earlier while EPS beat the $1.21 consensus by $0.20.

Q2 still sets the tone

The same report left FY 2026 guidance at 5.300-5.400 EPS, and analysts in the same coverage set a current-year view of 5.36 EPS, leaving little room between company guidance and Street expectations.

That gap matters because the shares already sit close to the $124.97 12-month high, while the market value stood at $13.73 billion in the latest trading snapshot.

Ownership stayed active

New institutional buying also kept attention on the name: one filing cited a new 109,761-share stake valued at $12.212 million, while another pointed to a $12.21 million position in the second quarter.

For investors, the comparison is straightforward - a $0.20 EPS beat, a 1.3% revenue decline, and a stock price above $123 all point to a valuation that is already carrying a good deal of the post-earnings optimism.

Diagnostics remains the core

Revvity's business still centers on life sciences and diagnostics products such as reagents, laboratory instruments, workflow automation and software analytics, which is the operating mix behind the margin discussion in the Q2 print.

That mix helps explain why the market is still assigning the name a premium multiple even after the August 4 results.

RVTY at a glance

As of August 25, 2026, RVTY traded at $123.08, with a 52-week range of $81.22 to $124.97 and a market cap of $13.73 billion.

Company

Company: Revvity Inc.
ISIN: US76155R1086
Ticker: RVTY
Exchange: NYSE
Sector / Industry: Health Care / Life Sciences Tools & Services
Index membership: S&P 500
Price (as of August 25, 2026, 3:59 p.m. ET): $124.79 USD
Market cap: $13.73 billion (as of August 25, 2026)

More on Revvity stock

The company sells reagents, instruments, automation systems and software used in diagnostics and research, which keeps the revenue mix tied to both consumables and higher-margin recurring software work.

More on Revvity stock

As of August 25, 2026, Revvity stock was priced at $124.79, with extended trading at $124.87. The latest market snapshot also showed a 52-week range from $81.22 to $124.97.

Disclaimer...

en | US76155R1086 | REVVITY INC. | boerse | 70002906 | bgmi